Regeneron Alternatives & Competitors
12 companies similar to Regeneron
NextRNA Therapeutics
Leading The Next Revolution of RNA-directed Therapeutics
Boston, United States
CRISPR Therapeutics
Gene-based medicines for patients with serious diseases
Boston, United States
Cytokinetics
Empowering Muscle Empowering Lives
South San Francisco, Unit...
Interius BioTherapeutics
Interius is developing new ways to engineer cells inside the human body, right where they...
Philadelphia, United Stat...
Track all Regeneron competitors
Get real-time alerts when any of these companies raise funding, hire, or show growth signals.
Editas Medicine
What If You Could Repair Broken Genes?
Cambridge, United States
Retex Pharmaceuticals
Watertown, United States
Mozart Therapeutics, Inc.
Orchestrating the Immune System
Seattle, United States
Sarepta Therapeutics
Dragging Tomorrow Into Today.
Cambridge, United States
RIGImmune Inc.
Targeted non-LNP Delivery of RNA Therapeutics
Farmington, United States
Prime Medicine, Inc.
Delivering on the promise of Prime Editing
Cambridge, United States
myTomorrows
Helping patients discover and access treatments
Amsterdam, The Netherland...
PTC Therapeutics, Inc.
We're committed to a single purpose: Extending life’s moments for patients with rare disea...
About Regeneron
Research and Development, Clinical Trials Management, Biologic Drug Development, Genetic Therapy Solutions, Scientific Publications
Patients with Serious Diseases, Healthcare Providers, Scientific Community, Investors, Medical Researchers
B2B, B2C, B2D
Product Sales, Licensing, Service Fee
Frequently Asked Questions
Don't just read about them. Follow them.
BounceWatch watches Regeneron and millions of other companies. When one raises money, hires quickly or changes its product, we tell you the same day.
Compiled from the BounceWatch company index. We last looked at Regeneron on 22 Jun 2026. The 12 companies listed here were last checked between 9 Jan 2026 and 3 Jul 2026. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.